Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

Part of paid clinical trials in Pasedena, Texas.

Sponsor
Ebima Clifford Okundaye
Study ID
NCT06866236
Phase
PHASE2/PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Acute Kidney Injury
  • Chronic Kidney Diseases
  • Kidney Failure

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • QRX-3 — DRUG
    capsule

Study Details

Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.

Key Dates

Start date
Oct 31, 2025
Status verified
Aug 2025
Primary completion
Oct 31, 2026
Completion
Jul 31, 2027

Study Design

Enrollment
3,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: intervention
    QRX-3 - two capsules orally twice daily
  • Placebo Comparator: placebo
    placebo pill - one capsule orally twice daily

Primary Outcome Measure

change in Glomerular filtration rate [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
Neukidney IncPasedenaTexas77504
Ebima C Okundaye
[email protected]
8328316135

Find similar trials in Pasedena, TX

By research site
Neukidney Inc· Pasedena, TX

Related Studies